Community‐Based Personalised Lifestyle Intervention Guided by Intermittent Continuous Glucose Monitoring in Adults With Type 2 Diabetes: A Multicentre Randomised Controlled Trial
Primary result · HbA1cResult — go to the resultAdjusted intervention-minus-control difference −0.09 percentage points 95% CI −0.38 to 0.21Authors' conclusion
The intervention did not significantly improve glycaemic or cardiometabolic outcomes beyond usual community care.
Study context
- Population
- Adults with T2D and pre-randomisation HbA1c > 7.0%, community-based171 analysed
- Participants
- 180 adults
- Comparison
- Continuous glucose monitoring (CGM)-guided personalised lifestyle intervention vs usual community diabetes management
- Primary endpoint
- HbA1c, analysed using multiple-imputation ANCOVA adjusted for baseline HbA1c and community site
- Follow-up
- Month 3
Methodological detailsmulticentre, open-label, Randomised 1:1; follow-up 12 months
- Multicentre
- Open-label
- Randomised 1:1; follow-up 12 months
Primary result
HbA1c
Adjusted intervention-minus-control difference
−0.09 percentage points
95% CI −0.38 to 0.21
P = 0.573
Interventionvs Control
adjusted intervention-minus-control difference −0.09 percentage points (95% CI −0.38 to 0.21); P = 0.573
As reported in the abstract
Secondary outcomes
HbA1c at Months 6 and 12
- No significant between-group HbA1c differences at Months 6 or 12
Secondary outcomes
- Secondary outcomes showed no consistent benefit
Month 3 responder outcomes
- Two responder outcomes nominally favoured the intervention; neither significant after multiplicity adjustment
- both q = 0.104
Baseline subgroups (exploratory) · Month 3
- No baseline subgroup with greater Month 3 benefit
- Exploratory analyses
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Community‐Based Personalised Lifestyle Intervention Guided by Intermittent Continuous Glucose Monitoring in Adults With Type 2 Diabetes: A Multicentre Randomised Controlled Trial. Diabetes Obes Metab. Published 12 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →